In vitro effects of serotonin and noradrenaline reuptake inhibitors on human platelet adhesion and coagulation
2012 (English)In: Pharmacological Reports, ISSN 1734-1140, Vol. 64, no 4, 979-983 p.Article in journal (Refereed) Published
Background: Although several studies show that there is an increased risk of bleeding events during antidepressant treatment with selective serotonin reuptake inhibitors (SSRIs), few studies show direct effects in vitro of SSRIs on hemostasis. less thanbrgreater than less thanbrgreater thanMethods: This study was undertaken to investigate the effects on platelet adhesion and plasma coagulation (APTT and PT) of two common SSRIs, citalopram and sertraline, the selective noradrenaline reuptake inhibitor reboxetine, and the serotonin and noradrenaline reuptake inhibitor venlafaxine. less thanbrgreater than less thanbrgreater thanResults: None of the compounds affected plasma coagulation significantly but all compounds except for venlafaxine inhibited platelet adhesion by approximately 50% or more at the highest concentration (100 mu g/l, p andlt; 0.01). The potency of respective compound to inhibit platelet adhesion to both collagen and fibrinogen surfaces was in the following order; citalopram andgt; sertraline andgt; reboxetine. In contrast, venlafaxine caused a weak but statistically significant increased platelet adhesion to fibrinogen. less thanbrgreater than less thanbrgreater thanConclusion: This study showed that sertraline, citalopram and reboxetine direct and acutely decrease platelet adhesion to both collagen and fibrinogen in vitro. These results also indicate that increased risk for bleeding complications in antidepressant users may not only be explained by depletion of serotonin in platelets.
Place, publisher, year, edition, pages
Inst. of Pharmacology, Polish Acad. of Sciences , 2012. Vol. 64, no 4, 979-983 p.
platelet activation, blood coagulation, SSRI, antidepressive agents, adverse effects
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-86662DOI: 10.1016/s1734-1140(12)70894-0ISI: 000310420500022OAI: oai:DiVA.org:liu-86662DiVA: diva2:580080
Funding Agencies|Carl Gustav and Lilly Lennhoffs Foundation at the Swedish Academy of Pharmaceutical Sciences||2012-12-202012-12-202014-10-28Bibliographically approved